# Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

> **NCT01346969** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 68 (actual)

## Conditions studied

- Reduction in Hypertrophic Skin Scarring

## Interventions

- **DRUG:** EXC 001
- **DRUG:** EXC 001
- **DRUG:** EXC 001
- **DRUG:** EXC 001

## Key facts

- **NCT ID:** NCT01346969
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-01
- **Primary completion:** 2012-04-16
- **Final completion:** 2012-04-16
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01346969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01346969, "Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01346969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*